Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 442 matching trials from the live ClinicalTrials.gov search.
Filters: "motor neuron disease" Condition: ALS Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of VRG50635 in Healthy Volunteers

NCT06286475
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VRG50635, Placebo
Drug
Lead sponsor
Verge Genomics
Industry
Eligibility
19 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 15, 2026, 3:20 AM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

NCT02414230
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS

NCT02469675
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Amyotrophic Lateral Sclerosis (ALS)
Interventions
Transcranial magnetic stimulation, Median nerve stimulation, Cervical transcutaneous stimulation
Device
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 15, 2026, 3:20 AM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 15, 2026, 3:20 AM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in ALS Participants

NCT04248465
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Placebo, Ravulizumab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 15, 2026, 3:20 AM EDT
Terminated Phase 3 Interventional Results available

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

NCT03836716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Orange, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Results available

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

NCT03241784
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Autologous T-regulatory lymphocytes, Interleukin-2
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ozanezumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03160898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
47
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.

NCT02750982
View directory record Official record
Conditions
Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, Stroke, Spinal Cord Injury
Interventions
Laughter Therapy
Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

NCT01906658
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Repository corticotropin injection
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

Dexpramipexole Renal PK Study

NCT01424176
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Interventions
Dexpramipexole (dose 1), Dexpramipexole (dose 2)
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Brooklyn Center, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS

NCT03202017
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Expiratory Muscle Strength Training (EMST), EMST + Lung Volume Recruitment (LVR)
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 15, 2026, 3:20 AM EDT
Active, not recruiting Phase 3 Interventional

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ION363, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
10 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Terminated No phase listed Observational

Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology

NCT00718107
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 15, 2026, 3:20 AM EDT
Recruiting Not applicable Interventional

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

NCT05936619
View directory record Official record
Conditions
Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Brainstem Stroke, Paralysis, Brain-computer Interface
Interventions
Mind Extender (MindEx)
Device
Lead sponsor
Nader Pouratian
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of High Doses of Zinc in ALS Patients

NCT01259050
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zinc and Copper
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 15, 2026, 3:20 AM EDT
Recruiting Not applicable Interventional

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
Interventions
Placement of the BrainGate2 sensor(s) into the motor-related cortex
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2038
U.S. locations
6
States / cities
Sacramento, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PREVENT ALL ALS Study

NCT06581861
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial Nuedexta in Subjects With ALS

NCT01806857
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Nuedexta, Matching Placebo
Drug
Lead sponsor
Center for Neurologic Study, La Jolla, California,
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 15, 2026, 3:20 AM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

NCT04288856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Not applicable Interventional Results available

Remotely Supervised tDCS for Slowing ALS Disease Progression

NCT04866771
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham tDCS + anodal tDCS
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 15, 2026, 3:20 AM EDT
Recruiting Not applicable Interventional

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

NCT07454733
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Video recording, Notes Instruction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 3:20 AM EDT
Completed Not applicable Interventional Results available

A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis

NCT01119001
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
P300 Brain Computer Interface Keyboard
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 15, 2026, 3:20 AM EDT